Literature DB >> 17026793

Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer.

Shelley Dranko1, Connie Kinney, Ramesh K Ramanathan.   

Abstract

Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer. The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17026793     DOI： 10.3816/CCC.2006.n.040

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN： 1533-0028            Impact factor:   4.481


  5 in total

Review 1.  Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.

Authors:  Shruthi Harish Bindiganavile; Nita Bhat; Andrew G Lee; Dan S Gombos; Nagham Al-Zubidi
Journal:  J Immunother Precis Oncol       Date:  2021-02-25

2.  Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer.

Authors:  M Fakih; M Vincent
Journal:  Curr Oncol       Date:  2010-07       Impact factor: 3.677

3.  Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.

Authors:  Durga S Borkar; Mario E Lacouture; Surendra Basti
Journal:  Support Care Cancer       Date:  2012-11-15       Impact factor: 3.603

Review 4.  Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials.

Authors:  Joshua Seth Eaton; Paul E Miller; Mark J Mannis; Christopher J Murphy
Journal:  J Ocul Pharmacol Ther       Date:  2015-11-05       Impact factor: 2.671

5.  Use of amniotic membrane graft in the surgical management of cicatricial ectropion associated with cetuximab therapy.

Authors:  Kateki Vinod; Vicente Diaz
Journal:  J Surg Case Rep       Date:  2015-01-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.